# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-23-015281
Filing Date
2023-04-27
Accepted
2023-04-27 16:13:51
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | amlx-defa14a-2023-additi.htm | DEFA14A | 40348
2 | GRAPHIC | img43653419_0.jpg | GRAPHIC | 419540
3 | GRAPHIC | img43653419_1.jpg | GRAPHIC | 387134
| Complete submission text file | 0000950170-23-015281.txt |  | 1151998

Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-41199 | Film No.: 23857036
SIC: 2834 Pharmaceutical Preparations